| Literature DB >> 32008161 |
Jun Lyu1, Zhiying Li2, Huiyi Wei3, Dandan Liu2, Xiaoxian Chi2, Da-Wei Gong4, Qingbin Zhao5.
Abstract
AIMS: Type 2 diabetes mellitus (T2DM) is now very prevalent in China. Due to the lower rate of controlled diabetes in China compared to that in developed countries, there is a higher incidence of serious cardiovascular complications, especially acute coronary syndrome (ACS). The aim of this study was to establish a potent risk predictive model in the economically disadvantaged northwest region of China, which could predict the probability of new-onset ACS in patients with T2DM.Entities:
Keywords: Cardiovascular disease; Northwest China; Risk predictive model; Type 2 diabetes mellitus
Mesh:
Substances:
Year: 2020 PMID: 32008161 PMCID: PMC7220880 DOI: 10.1007/s00592-020-01484-x
Source DB: PubMed Journal: Acta Diabetol ISSN: 0940-5429 Impact factor: 4.280
Participant characteristics
| Variables | Training set ( | Validation set (n = 137) | |
|---|---|---|---|
| Status, | 0.153 | ||
| 0 = without ACS | 182 (57.1) | 88 (64.2) | |
| 1 = with ACS | 137 (42.9) | 49 (35.8) | |
| Sex, | 0.64 | ||
| 1 = male | 219 (68.7) | 91 (66.4) | |
| 2 = female | 100 (31.3) | 46 (33.6) | |
| Age, years | 56.7 ± 10.2 | 57.2 ± 9.9 | 0.591 |
| T2DM duration, years | 8.6 ± 5.7 | 9.3 ± 6.7 | 0.244 |
| Family history of CHD, | 0.141 | ||
| 1 = yes | 38 (11.9) | 10 (7.3) | |
| 2 = no | 281 (88.1) | 127 (92.7) | |
| Hypertension, | 0.610 | ||
| 1 = yes | 155 (48.6) | 63 (46.0) | |
| 2 = no | 164 (51.4) | 74 (54.0) | |
| Drinking, | 0.013 | ||
| 1 = yes | 37 (11.6) | 28 (20.4) | |
| 2 = no | 282 (88.4) | 109 (79.6) | |
| Smoking, | 0.879 | ||
| 1 = yes | 121 (37.9) | 53 (38.7) | |
| 2 = no | 198 (62.1) | 84 (61.3) | |
| Body mass index, kg/m2 | 25.8 ± 3.7 | 25.2 ± 3.9 | 0.131 |
| Systolic blood pressure, mmHg | 132.7 ± 18.1 | 130.7 ± 15.7 | 0.262 |
| Diastolic blood pressure, mmHg | 78.4 ± 10.2 | 76.8 ± 9.7 | 0.124 |
| Haemoglobin Alc, % | 8.1 ± 1.8 | 8.1 ± 1.8 | 0.879 |
| Fasting blood glucose, mmol/L | 8.1 ± 2.9 | 7.7 ± 2.6 | 0.195 |
| Total cholesterol, mmol/L | 4.0 ± 0.9 | 4.1 ± 1.0 | 0.271 |
| Triglyceride, mmol/L | 1.9 ± 1.6 | 1.8 ± 1.4 | 0.623 |
| High-density lipoprotein cholesterol, mmol/L | 1.0 ± 0.3 | 1.0 ± 0.3 | 0.646 |
| Low-density lipoprotein cholesterol, mmol/L | 2.4 ± 0.8 | 2.5 ± 0.8 | 0.175 |
| Apolipoprotein A, g/L | 1.1 ± 0.2 | 1.2 ± 0.2 | 0.342 |
| Apolipoprotein B, g/L | 0.8 ± 0.2 | 0.8 ± 0.2 | 0.341 |
| Apolipoprotein E, mg/L | 35.8 ± 16.7 | 35.6 ± 16.5 | 0.920 |
| Lipoprotein(a), mg/L | 154.9 ± 162.5 | 153.8 ± 169.9 | 0.950 |
| Estimated glomerular filtration rate, ml/min/1.73 m2 | 123.6 ± 34.1 | 124.9 ± 30.4 | 0.688 |
| Blood urea nitrogen, mmol/L | 5.8 ± 1.8 | 5.7 ± 1.6 | 0.591 |
| Serum creatinine, mmol/L | 62.1 ± 22.1 | 59.5 ± 15.4 | 0.210 |
| Cystatin C, mg/L | 0.8 ± 0.3 | 0.8 ± 0.2 | 0.309 |
| Serum uric acid, μmol/L | 334.2 ± 80.1 | 333.4 ± 86.1 | 0.920 |
| D-dimer, mg/L | 0.5 ± 0.5 | 0.4 ± 0.2 | 0.419 |
| Gamma-glutamyl transpeptidase, U/L | 31.1 ± 24.0 | 34.2 ± 41.2 | 0.320 |
| Platelet count, × 109/L | 193.9 ± 55.6 | 189.5 ± 52.7 | 0.436 |
| Platelet distribution width, fL | 15.5 ± 3.0 | 15.5 ± 3.1 | 0.917 |
| Mean platelet volume, fL | 11.7 ± 1.3 | 11.7 ± 1.3 | 0.842 |
| Platelet–larger cell ratio, % | 38.3 ± 10.3 | 38.8 ± 10.1 | 0.658 |
| Plateletcrit, % | 0.2 ± 0.1 | 0.2 ± 0.1 | 0.285 |
ACS, acute coronary syndrome; T2DM, type 2 diabetes mellitus; CHD, coronary heart disease
Multivariate logistic regression analysis (training set)
| Variables | OR | 95% CI | |
|---|---|---|---|
| Age | 1.067 | 1.033–1.103 | < 0.001 |
| Body mass index | 1.139 | 1.055–1.235 | 0.001 |
| Diabetes duration | 0.943 | 0.893–0.992 | 0.027 |
| Systolic blood pressure | 1.031 | 1.010–1.053 | 0.005 |
| Diastolic blood pressure | 0.940 | 0.903–0.969 | < 0.001 |
| Low-density lipoprotein cholesterol | 0.547 | 0.371–0.792 | 0.002 |
| Serum uric acid | 1.008 | 1.004–1.012 | < 0.001 |
| Lipoprotein(a) | 1.002 | 1.000–1.004 | 0.028 |
| Hypertension | |||
| 1 = yes | Reference | ||
| 2 = no | 0.417 | 0.232–0.741 | 0.003 |
| Drinking | |||
| 1 = yes | Reference | ||
| 2 = no | 1.497 | 0.621–3.864 | 0.383 |
OR, odds ratio; CI, confidence interval
Fig. 1A nomogram for predicting the probability of new-onset ACS in T2DM patients. The nomogram is used by scoring each variable on its corresponding score scale. The scores for all variables are then summed up to obtain the total score, and a vertical line is drawn from the total point row to indicate the estimated probability of new-onset ACS in T2DM patients. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; UA, uric acid; Lp(a), lipoprotein(a); Hp, hypertension history; ACS, acute coronary syndrome; and T2DM, type 2 diabetes mellitus
Fig. 2ROC curves a from the training set and b from the validation set
Fig. 3Calibration plots. The shadow line represents a perfect prediction by an ideal model, and the dotted line shows the performance of the training set (a) and validation set (b). The Hosmer–Lemeshow test yielded a P value of 0.705 in the training set (a) and 0.823 in the validation set (b)
Fig. 4Decision curve analysis. Area within the dotted line, the grey solid line, and the black solid line represents the net benefit. The black solid line indicates that all samples are negative and all were not treated. The grey solid line indicates that all samples were positive and were treated a from the training set and b from the validation set